Integration of cancer genomics with treatment selection: From the genome to predictive biomarkers

Cancer

Volumn 119, Issue 22, 2013, Pages 3914-3928

  Ow, Thomas J ^a   Sandulache, Vlad C ^b   Skinner, Heath D ^c   Myers, Jeffrey N ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

biologic markers; clinical trials as topic; computational biology; genomics; molecular targeted therapy; neoplasms; systems biology; therapeutics

Indexed keywords

AMINOPTERIN; BEVACIZUMAB; BORTEZOMIB; BOSUTINIB; CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FLUTAMIDE; FOLIC ACID ANTAGONIST; GEFITINIB; IMATINIB; IPILIMUMAB; LAPATINIB; LEUPRORELIN; MONOCLONAL ANTIBODY; NILOTINIB; NUCLEOTIDE DERIVATIVE; PANITUMUMAB; PERTUZUMAB; RITUXIMAB; ROMIDEPSIN; SORAFENIB; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VEMURAFENIB; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANDROGEN DEPRIVATION THERAPY; BREAST CANCER; BREAST METASTASIS; CANCER GENETICS; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CHILDHOOD LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; CUTANEOUS MELANOMA; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC TRANSCRIPTION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HETEROZYGOSITY LOSS; HUMAN; IMMUNOPRECIPITATION; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; MOUTH SQUAMOUS CELL CARCINOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING;

BIOLOGIC MARKERS; CLINICAL TRIALS AS TOPIC; COMPUTATIONAL BIOLOGY; GENOMICS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SYSTEMS BIOLOGY; THERAPEUTICS;

GENOMICS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887079931     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28304     Document Type: Review

References (97)

1. Watson JD, Crick FH,. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature. 1953; 171: 737-738.
2. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell. 2000; 100: 57-70.
3. Shinawi M, Cheung SW,. The array CGH and its clinical applications. Drug Discov Today. 2008; 13: 760-770.
4. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998; 20: 207-211.
5. Lucito R, Healy J, Alexander J, et al. Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. Genome Res. 2003; 13: 2291-2305.
6. Carter NP,. Methods and strategies for analyzing copy number variation using DNA microarrays. Nat Genet. 2007; 39 (suppl 7): S16-S21.
7. Kallioniemi A,. CGH microarrays and cancer. Curr Opin Biotechnol. 2008; 19: 36-40.
8. Morris LG, Taylor BS, Bivona TG, et al. Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci U S A. 2011; 108: 19024-19029.
9. Rodon J, Dienstmann R, Serra V, Tabernero J,. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013; 10: 143-153.
10. International HapMap Consortium, Frazer KA, Ballinger DG, et al. A second generation human haplotype map of over 3.1 million SNPs. Nature. 2007; 449: 851-861.
11. 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al. A map of human genome variation from population-scale sequencing. Nature. 2010; 467: 1061-1073.
12. Bacolod MD, Schemmann GS, Giardina SF, Paty P, Notterman DA, Barany F,. Emerging paradigms in cancer genetics: some important findings from high-density single nucleotide polymorphism array studies. Cancer Res. 2009; 69: 723-727.
13. Shen R, Fan JB, Campbell D, et al. High-throughput SNP genotyping on universal bead arrays. Mutat Res. 2005; 573: 70-82.
14. Chen Y, Chen C,. DNA copy number variation and loss of heterozygosity in relation to recurrence of and survival from head and neck squamous cell carcinoma: a review. Head Neck. 2008; 30: 1361-1383.
15. Xu C, Liu Y, Wang P, et al. Integrative analysis of DNA copy number and gene expression in metastatic oral squamous cell carcinoma identifies genes associated with poor survival [serial online]. Mol Cancer. 2010; 9: 143.
16. Xu C, Wang P, Liu Y, et al. Integrative genomics in combination with RNA interference identifies prognostic and functionally relevant gene targets for oral squamous cell carcinoma [serial online]. PLoS Genet. 2013; 9: e1003169.
17. Wu X, Spitz MR, Lee JJ, et al. Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila). 2009; 2: 617-624.
18. Sanger F, Coulson AR,. A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol. 1975; 94: 441-448.
19. Sanger F, Nicklen S, Coulson AR,. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977; 74: 5463-5467.
20. Mardis ER,. Next-generation DNA sequencing Methods. Annu Rev Genomics Hum Genet. 2008; 9: 387-402.
21. Shendure J, Lieberman Aiden E,. The expanding scope of DNA sequencing. Nat Biotechnol. 2012; 30: 1084-1094.
22. Ng SB, Turner EH, Robertson PD, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature. 2009; 461: 272-276.
23. Yu Y, Wu BL, Wu J, Shen Y,. Exome and whole-genome sequencing as clinical tests: a transformative practice in molecular diagnostics. Clin Chem. 2012; 58: 1507-1509.
24. Robinson PN, Krawitz P, Mundlos S,. Strategies for exome and genome sequence data analysis in disease-gene discovery projects. Clin Genet. 2011; 80: 127-132.
25. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011; 333: 1154-1157.
26. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333: 1157-2260.
27. Pennisi E,. Genomics. ENCODE project writes eulogy for junk DNA. Science. 2012; 337: 1159-1161.
28. Zhang J, Wu G, Miller CP, et al. St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project l. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013; 45: 602-612.
29. Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013; 45: 478-486.
30. Gupta RA, Shah N, Wang KC, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464: 1071-1076.
31. Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013; 110: 6021-6026.
32. Reis-Filho JS, Pusztai L,. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet. 2011; 378: 1812-1823.
33. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-2826.
34. Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004; 5: 489-500.
35. Wang Z, Gerstein M, Snyder M,. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009; 10: 57-63.
36. Heyn H, Esteller M,. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet. 2012; 13: 679-692.
37. Shen J, Stass SA, Jiang F,. MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett. 2013; 329: 125-136.
38. Furey TS,. ChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactions. Nat Rev Genet. 2012; 13: 840-852.
39. ENCODE Project Consortium, Dunham I, Kundaje A, et al. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489: 57-74.
40. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455: 1061-1068.
41. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61-70.
42. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474: 609-615.
43. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487: 330-337.
44. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489: 519-525.
45. Farber S, Diamond LK,. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948; 238: 787-793.
46. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989; 320: 479-484.
47. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011; 365: 107-118.
48. Schwaber JF, Rosen FS,. Induction of human immunoglobulin synthesis and secretion in somatic cell hybrids of mouse myeloma and human B lymphocytes from patients with agammaglobulinemia. J Exp Med. 1978; 148: 974-986.
49. Galfre G, Milstein C, Wright B,. Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG. Nature. 1979; 277: 131-133.
50. Weiner LM, Surana R, Wang S,. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010; 10: 317-327.
51. Riechmann L, Clark M, Waldmann H, Winter G,. Reshaping human antibodies for therapy. Nature. 1988; 332: 323-327.
52. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337-345.
53. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567-578.
54. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
55. Ebos JM, Kerbel RS,. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011; 8: 210-221.
56. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
57. Krause DS, Van Etten RA,. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005; 353: 172-187.
58. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G,. Structural organization of the bcr gene and its role in the Ph′ translocation. Nature. 1985; 315: 758-761.
59. Maxwell SA, Kurzrock R, Parsons SJ, et al. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res. 1987; 47: 1731-1739.
60. Kurzrock R, Kloetzer WS, Talpaz M, et al. Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood. 1987; 70: 233-236.
61. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 1031-1037.
62. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
63. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366: 707-714.
64. Muller AJ, Scherle PA,. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer. 2006; 6: 613-625.
65. Maloney DG,. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012; 3661: 2008-2016.
66. Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P,. Ipilimumab. Nat Rev Drug Discov. 2011; 10: 411-412.
67. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
68. Turk B,. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov. 2006; 5: 785-799.
69. Bolden JE, Peart MJ, Johnstone RW,. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5: 769-784.
70. Kadin ME, Vonderheid EC,. Targeted therapies: denileukin diftitox-a step towards a "magic bullet" for CTCL. Nat Rev Clin Oncol. 2010; 7: 430-432.
71. Pouget JP, Navarro-Teulon I, Bardies M, et al. Clinical radioimmunotherapy-the role of radiobiology. Nat Rev Clin Oncol. 2011; 8: 720-734.
72. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LAJ, Kinzler KW,. Cancer genome landscapes. Science. 2013; 339: 1546-1558.
73. Altmann A, Weber P, Bader D, Preuss M, Binder EB, Muller-Myhsok B,. A beginner's guide to SNP calling from high-throughput DNA-sequencing data. Hum Genet. 2012; 131: 1541-1554.
74. Krumm N, Sudmant PH, Ko A, et al. Copy number variation detection and genotyping from exome sequence data. Genome Res. 2012; 22: 1525-1532.
75. Gonzalez-Angulo AM, Hennessy BT, Mills GB,. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol. 2010; 28: 2777-2783.
76. Pickering CR, Zhang J, Yoo SY, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 2013; 3: 770-781.
77. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001; 344: 1052-1056.
78. Turner NC, Lord CJ, Iorns E, et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 2008; 27: 1368-1377.
79. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007; 12: 395-402.
80. Sano D, Xie TX, Ow TJ, et al. Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer. Clin Cancer Res. 2011; 17: 6658-6670.
81. Skinner HD, Sandulache VC, Ow TJ, et al. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res. 2012; 18: 290-300.
82. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007; 357: 2552-2561.
83. Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, et al. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res. 2011; 17: 3733-3741.
84. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008; 68: 3389-3395.
85. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
86. Boehm JS, Hahn WC,. Towards systematic functional characterization of cancer genomes. Nat Rev Genet. 2011; 12: 487-498.
87. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359: 1757-1765.
88. Rodon J, Saura C, Dienstmann R, et al. Molecular prescreening to select patient population in early clinical trials. Nat Rev Clin Oncol. 2012; 9: 359-366.
89. Meric-Bernstam F, Mills GB,. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol. 2012; 9: 542-548.
90. Munoz J, Kurzrock R,. Targeted therapy in rare cancers-adopting the orphans. Nat Rev Clin Oncol. 2012; 9: 631-642.
91. Arteaga CL, Baselga J,. Impact of genomics on personalized cancer medicine. Clin Cancer Res. 2012; 18: 612-618.
92. Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011; 1: 44-53.
93. Kiyotani K, Mushiroda T, Imamura CK, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010; 28: 1287-1293.
94. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368: 1199-1209.
95. Murugaesu N, Chew SK, Swanton C,. Adapting clinical paradigms to the challenges of cancer clonal evolution. Am J Pathol. 2013; 182: 1962-1971.
96. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467: 1114-1117.
97. Martinez P, Birkbak NJ, Gerlinger M, et al. Parallel evolution of tumor subclones mimics diversity between tumors. J Pathol. 2013; 230: 356-364.